Wolwo Pharma obtained the summary report of Phase I clinical trial for Aspergillus flavus puncture solution
I'm PortAI, I can summarize articles.
Wolwo Pharma has completed the Phase I clinical trial of the Aspergillus flavus puncture solution and obtained the summary report. The study shows that the drug has good safety within the set dosage range, with no serious adverse reactions occurring. Some subjects experienced delayed reactions, which may be related to the characteristics of the fungus. The specificity for each dosage exceeded 95%, and the sensitivity reached 95% at 55000 DU/mL. The researchers recommend conducting subsequent clinical studies at doses of 55000 DU/mL and above, and exploring strategies to reduce delayed reactions
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments